NCT05944848View on ClinicalTrials.gov

A Study of CL-197 Capsules in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

January 20, 2024

Study Completion Date

January 20, 2024

Conditions
HIV-1
Interventions
DRUG

1 mg CL-197 capsules

Single oral dose of 1 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

DRUG

10 mg CL-197 capsules or CL-197 placebo

Single oral dose of 10 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

DRUG

30 mg CL-197 capsules or CL-197 placebo

Single oral dose of 30 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

DRUG

60 mg CL-197 capsules or CL-197 placebo

Single oral dose of 60 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

DRUG

100 mg CL-197 capsules or CL-197 placebo

Single oral dose of 100 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

Trial Locations (1)

Unknown

The Fifth Medical Center of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Henan Genuine Biotech Co., Ltd.

INDUSTRY